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Abstract
Background: Bangladesh, with a population of 160 million and nearly half being women, has the 4th highest rate
of cervical carcinoma deaths in the world. It is projected that ∼500,000 of these women would die of this entirely
preventable cancer by 2030. HPV vaccination is not widely offered in Bangladesh. This pilot study is designed to
find out the prevalence of rare and multi-viral high-risk HPV (hrHPV) subtype(s) infection which may help strategize
a large scale vaccination program in tackling cervical carcinoma in the country.
Methods: Forty cases of cervical High-Grade squamous intraepithelial lesion (HSIL) and Squamous cell carcinoma
(SqCa) were collected. DNA was extracted from tissue representing HSIL and SqCa and multiplex PCR was run to
identify all 15 hrHPV subtypes along with known positive controls.
Results: Of the total, 27 cases were biopsies/cones and 13 were hysterectomies including 5 HSIL and 35 SqCa.
Infection caused by rare subtypes, hrHPV 45 and 52, were found in only two cases. Multi-subtype infection,
detected in 28 % cases, was limited to HPV16/18 in all cases but one; one case showed hrHPV16/52 combination.
Conclusion: A remarkable homogeneity of hrHPV 16 infection is noted in women with HSIL & SqCa in this country
in these limited samples. This finding is in sharp contrast to the reports from western countries of frequent multi-
viral and rare subtype hrHPV infection. This pilot study suggests that a vaccination program may be highly effective
in controlling cervical cancer there. A larger study, however, is required to ratify the findings.
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Background
Cervical Cancer Global Crisis Card reports that
Bangladesh ranks 4th in cervical carcinoma deaths in
the world after India, China and Brazil (WHO). Inci-
dence of cervical cancer is 19.2 per 100,000 women in
Bangladesh [1]. The country is densely populated with
54.38 million women aged 15 years or older who are at
risk of developing cervical cancer [2]. By 2030 an esti-
mated 500,000 women in the middle and low income
countries will die of this disease (WHO). According to a
published report an estimated 6582 women per 100,000
die of cervical cancer annually (crude mortality rate of
8.7 %) [3, 4].
Human papillomavirus (HPV) infection causes cervical
cancer and its precursor lesions in majority, if not all,
cases [5]. Persistent infection with one or more types of
high-risk HPV (hrHPV) is considered crucial in disease
progression from cervical intraepithelial neoplasia (CIN)
to invasive carcinoma [6]. More than 170 types of HPV
have been identified until now [7], of which 40 distinct
HPV types are known to date to infect the genital tract
[8]. A meta-analysis of epidemiological studies desig-
nated 15 HPV types as high-risk types (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) because of
their significant association with progression to invasive
cervical carcinoma (ICC), and additional three (26, 53,
and 66) as probable high-risk types [9].
International Agency for Research on Cancer (IARC)
reported HPV 16 to be the most common type world-
wide followed by HPV 18, and together accounting for
>70 % of ICC cases [10]. Epidemiological studies have
shown that type-specific prevalence of HPV in cervical
cancers differs according to geographical regions [11].
The authors reported that HPV 16 to be the predomin-
ant subtype ranging from 45.9 % in Asia to 62.6 % in
Europe. The second most frequent subtype, HPV 18,
was reported in approximately 10–14 % [10]. World-
wide HPV 45, 31 and 33 were the next most frequent
types, except in Asia where HPV 58 and 52 were found
to be more frequent [10]. In another study, Bao et al.
[12] reported ten most common HPV subtypes detected
in invasive cervical carcinoma in Asia, e.g., HPV16, 18,
58, 33, 52, 45, 31, 35, 59, and 51.
Only a handful of studies are available in the literature
on the prevalence of hrHPV in Bangladesh. These stud-
ies were carried out in selected patient population, such
as, in female sex workers [13] and women with abnor-
mal cervical cytology in a tertiary care hospital [14]. Re-
cently Nahar et al. [15] reported a study on women
recruited from an urban center and a rural center. All,
except one, of these studies isolated HPV from cytologic
preparation without any histologic correlation. Banik et.
al [14] attempted to isolate HPV 16 and 18 from dys-
plastic tissue.
Multi-viral hrHPV infection has been reported to be
associated with cervical dysplasia [16] and carcinoma
[17]. It has been recently reported that as many as five
different sub-types of hrHPV are being present in high
grade dysplasia at a single anatomic location [18]. The
frequency of multi-viral infection in dysplasia/neoplasia
is not known in Bangladesh.
The current study attempts to identify the prevalence
of all 15 hrHPV subtypes in HSILs and SqCa, presence
of rare subtypes, and determine the frequency of multi-
viral subtype infection from lesional tissue. This infor-
mation would fill-up the void that exists in epidemio-
logical data now present on HPV infection in this
country. This information may also prove beneficial for
the mass scale HPV vaccination program in controlling
HPV infection and eventually saving numerous young
lives in this country.
Methods
This is a retrospective collaborative pilot study. The col-
laborating departments are the Departments of Pathology,
Women & Infants Hospital/Alpert Medical School of
Brown University, Providence, RI, USA; BSM Medical
University (BSMMU), Dhaka, Bangladesh; and Physicians
Reference Laboratory, Overland Park, KS, USA.
After obtaining approval from the Institutional review
board of BSMMU, Dhaka, Bangladesh and Institutional
Review Board of Women & Infants Hospital, 40 cases
comprising of 35 SqCa and 5 cervical HSIL (CIN 2/3)
diagnosed during August 2013 – January 2014 at the
Department of Pathology of BSMMU, were selected for
the study. Paraffin embedded tissue blocks were re-
trieved from the archive of Department of Pathology,
BSMMU and sent to the Women & Infants Hospital,
Providence, RI, USA without any patient unique identi-
fiers. At Women & Infants hospital, Hematoxylin and
eosin stained sections from each case were reviewed by
one pathologist (MRQ) to confirm the diagnosis and
affirm the presence of lesional areas for DNA extraction.
Five to 10, 5 μm tissue sections were obtained to ex-
tract DNA from the selected areas of formalin-fixed par-
affin embedded (FFPE) tissue samples by using QIAmp
DNA FFPE Kit. HPV testing was done using the propri-
etary COMPLeTe Care HPV test (Physicians Reference
Laboratory, Overland park, KS), a multiplex real-time
PCR test that simultaneously detected, typed and quanti-
fied all 15 high-risk HPV (hrHPV) subtypes. The tested
subtypes were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68, 73, and 82, as reported by a consensus from
several epidemiologic studies [9]. The method has been
described by these authors in a previously published
paper [17]. The target of COMPLeTe Care HPV test was
E7, an oncogene in the HPV genome, which usually gets
integrated into the host chromosome and plays a critical
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role in cervical carcinogenesis. The oncogenes E6 and
E7 are stable unlike capsid gene L1, which is reported to
be lost during integration.
Both absolute viral load and cell numbers were calcu-
lated from the quantitative standards included in each
run with the patient samples. The viral loads and ß-glo-
bin amounts were determined on the basis of the cross-
ing point (Cp) or crossing threshold (Ct) values above
their corresponding baselines in relation to the quantita-
tive standards [17]. Viral loads were normalized to 1000
cells. The quantification range of the assay is 10^1 to
10^6 copies/reaction and the qualitative lower limit of
detection is <10 copies/reaction. Copies <10 are quali-
fied simply as “positive”.
Results
A total of 40 cases were studied, including 35 SqCa and
5 HSIL. The age distribution is shown in Table 1. The
age range of the patients is 25–70 years, with a mean of
48.38 years and a median of 50 years (SD = 10.175). Of
the total 40 specimens, 27 (67.5 %) were cervical cones/
LEEPs or biopsies, and 13 (32.5 %) hysterectomies.
All but one case (N = 39) in this series were success-
fully amplified by multiplex PCR indicating the hrHPV
identification rate of 97.5 % in SqCa and HSIL speci-
mens in this study. HPV 16 was detected in 38 of 39
cases (97.4 %), either alone or in combination with HPV
18 (25.6 %). HPV 18 has been identified only in combin-
ation with HPV 16. Rare subtypes, HPV 52 and HPV 45,
were identified only in two cases. HPV 52 was identified
in combination with HPV 16 and HPV 52 (2.5 %). The
remaining case had a single infection by HPV 45.
Of the 35 cases of SqCa, DNA was amplified in all but
one case. Out of the HPV positive 34 cases, 33 (97 %)
had infection with HPV 16, either alone (N = 23) or in
combination with HPV 18 (N = 9), or in combination
with HPV 52 (N = 1). The single remaining case (2.9 %)
showed amplification of only HPV 45. Thus, of the total
of 34 SqCa, HPV 18 was present in 9 (26.5 %) patients
and HPV 52 in only one patient (2.9 %), both as multiple
subtype infections.
All the five cases of HSIL had infection with HPV 16
(100 %), and one of them also had co-infection with
HPV 18 (20 %).
Multi-subtype infection, mainly of HPV 16/18, was
present in 11 out of 39 (28 %) cases; ten of these were
SqCa and one was a case of HSIL. The normalized viral
load of each HPV subtype per 1000 cells is shown in Ta-
bles 2 and 3 shows the comparison of normalized viral
loads between HSIL and SqCa.
Discussion
Cervical carcinoma induced mortality and morbidity
is high and it is the second highest cause of cancer-
related deaths in women in Bangladesh [3]. HPV vac-
cination has recently been introduced in the country
and sparingly offered to young women. The bivalent
vaccine offers protection against hrHPV 16 and 18. It
also offers some cross protection against HPV 45, 31,
and 33 [19, 20]. The quadrivalent vaccine offers protection
against HPV 6, 11, 16, and 18 and some cross protection
against HPV 31, 33, 35, 39, 52, 58, and 59 [19–21].
As expected, hrHPV was detected in 97.5 % cases of
SqCa and HSIL examined. One test (2.5 %) failed which
could very well be attributed to any technical glitch.
HPV 16 was detected in overwhelming majority of cases
(38 of 39; 97.4 %), either alone or in combination with
HPV 18 and HPV 52. Interestingly HPV 18 was identi-
fied only in combination with HPV 16 in 10 cases
(25.6 %). Only in two cases, rare subtypes, e.g., HPV 52
and HPV 45 were identified. HPV 52 was identified in
combination with HPV 16. The remaining one case had
a single stand-alone infection by HPV 45. Although the
rare subtypes HPV are detected in fewer numbers of
cases now, they may potentially play an important role
in future in post-vaccination era. Of note that some cross
protection may be expected against these two rare sub-
types of HPV by the quadrivalent and bivalent HPV vac-
cines available in the country. Recently Nahar and her
colleagues reported HPV 66 in the country [15]. Of note,
no vaccine available now or in developmental phase (the
9-valent vaccine) offers any protection against hrHPV 66.
The current study has found that the rare hrHPV sub-
types are highly uncommon in this cervical carcinoma





N (%) Stratified by age groups
<30 years 30–44 years ≥45 years
HSIL (N= 5) CIN 2 1 (2.5 %) - 1 -
CIN 3 4 (10 %) - - 4
SqCa (N= 35) Grade I 2 (5 %) - 1 1
Grade II 18 (45 %) 1 3 14
Grade III 15 (37.5 %) - 7 8
Note: HSIL High grade squamous intraepithelial lesion, SqCa Squamous
cell carcinoma
Table 2 Normalized hrHPV viral loads
Subtypes N Viruses per 1000 cells
Range
HPV 16 37 Positive*–440,991
HPV 18 10 Positive*–751
HPV45 1 2100
HPV 52 1 22
Note: *Copies <10 are qualified as “positive”
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16 infection (97.4 %) in Bangladeshi women with cer-
vical SqCa and HSIL has been documented in this pilot
study. This is significantly different from the epidemio-
logic data reported from the western countries where
rare HPV subtypes are more frequently encountered
[18]. A larger study is needed to ratify the findings of
this pilot study.
Multi-subtype HPV infection was detected in 28 % cases
in this study. Fortunately, this was noted only as a com-
bination of HPV 16/18 and a single case of HPV16/52.
Multiple HPV subtypes infection consisting of rare sub-
types of HPV are more frequently reported in studies from
Western countries [18]. One can speculate that the social
and cultural practices may be the cause for this apparent
difference of findings.
Viral load of hrHPV is found to have significant asso-
ciation with the development of HSIL and the risk is
said to be enhanced with higher baseline HPV DNA
[22]. Viral load may thus serve as an indicator of risk of
disease progression, although lower viral load does not
necessarily mean lack of progression [19] or viral clear-
ance with no disease [23]. Individual immunity must
play a role in the pathogenesis of the disease. As ex-
pected and shown in Table 3, the viral loads of HPV 16
in HSILs were much higher than that of SqCa cases.
The HPV 16 viral copies were much higher in HSIL
(5329–152,973) than those in SqCa (Positive–440,991),
except in one case of SqCa which has the highest viral
load of 440,991/1000 cells. This finding is similar to
what is reported by Hui et al. [18]. The viral copies of
the two rare hrHPV subtypes were much lower com-
pared to HPV 16. Quddus et.al [17] previously reported
that a small number of recurrent tumors had higher
viral loads in their primary tumors.
Routine screening has successfully decreased hrHPV
related female genital tract lesion in the Western world.
But Bangladesh, being a developing nation, lacks com-
prehensive infrastructure for mass screening and early
intervention of HPV infection. Therefore, mass
immunization against the most prevalent hrHPV sub-
types may be an effective way to address the issue.
Fortunately even with its limited resources, Bangladesh
has established an efficient infrastructure for grass-root
level immunization program and has shown tremendous
success in childhood vaccination program. Without en-
during additional cost it appears possible that
Bangladesh can bring down cervical cancer deaths using
the existing infrastructure of childhood immunization
program. Knowing specific hrHPV subtypes in dysplastic
and neoplastic tissues would help the health care
workers to fight against the current subtype(s) induced
disease and also prepares for future should or when the
rare subtype(s) emerge.
Conclusions
A remarkable homogeneity of hrHPV 16 infection is
noted in women with HSIL & SqCa in this country in
this pilot study. This finding is in sharp contrast to the
reports from western countries of frequent multi-viral
and rare subtype hrHPV infection. This study suggests
that a vaccination program would be highly effective in
controlling cervical cancer should a larger study ratify
the findings of this pilot study.
Acknowledgements
The results of the study were presented in part at the 105th Annual Meeting
of the United States and Canadian Academy of Pathology (USCAP), Seattle,
WA, in March 2016.
Funding sources
No funding was received for this study.
Availability of data and material
De-identified data would be available for review for the Editorial Office.
Authors’ contributions
SA is the fellow in training and collected the specimens, worked on the
project and drafted the manuscript. PM carried the Multiplex Real Time PCR
tests. MK reviewed the H&E slides in Bangladesh to confirm the diagnosis.
CJS helped analyze the data. WDL worked in selecting the final cases and
helped in drafting the manuscript. MRQ conceived of the study, and
participated in its design and coordinated and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
Dr Manna works for Physicians Reference Laboratory. Remaining authors
declare no competing interest.
Consent for publication
No patient personal identifiers are reported. Use of residual tissue has been
approved by the Institutional Review Boards.
Ethics approval and consent to participate
The study has been approval by the Institutional Review Board of Women &
Infants Hospital, Providence, RI, USA and BSM Medical University, Dhaka,
Bangladesh. The study was conducted on residual paraffin embedded tissue
samples. No personal patient identifier is disclosed.
Author details
1Department of Pathology, Bangabandhu Sheikh Mujib Medical University,
Dhaka, Bangladesh. 2Physicians Reference Laboratory, Overland Park, KS, USA.
3Department of Pathology, Women & Infants Hospital & Alpert Medical
School of Brown University, 101 Dudley Street, Providence, RI 02905, USA.




N HPV Viruses per 1000 cells
Range
HGSIL (N = 5) HPV 16 5 2018–1,529,730
HPV 18 1 -
Inv SqCa (N = 35) HPV 16 33 Positive*–4,409,910
HPV 18 7 Positive*–751
HPV 45 1 -
HPV 52 1 -
Note: *Copies <10 are qualified as “positive”
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